Skip to main content

Advertisement

ADVERTISEMENT

News

News
09/03/2020
A long-term analysis of patients with localized and metastatic GIST determined there were survival differences associated with KIT mutation testing and other clinical variables.
A long-term analysis of patients with localized and metastatic GIST determined there were survival differences associated with KIT mutation testing and other clinical variables.
A long-term analysis of patients...
09/03/2020
Oncology
News
07/17/2020
Avapritinib had a manageable safety profile and demonstrated activity in patients with PDGFRA D842V-mutant GIST in the NAVIGATOR trial.
Avapritinib had a manageable safety profile and demonstrated activity in patients with PDGFRA D842V-mutant GIST in the NAVIGATOR trial.
Avapritinib had a manageable...
07/17/2020
Oncology
News
06/09/2020
After a median follow-up of 10 years, 3 years of adjuvant imatinib was associated with significantly improved RFS and OS compared with 1 year of imatinib, after surgery, in patients with high risk-GIST.
After a median follow-up of 10 years, 3 years of adjuvant imatinib was associated with significantly improved RFS and OS compared with 1 year of imatinib, after surgery, in patients with high risk-GIST.
After a median follow-up of 10...
06/09/2020
Oncology

Advertisement

News
05/15/2020
The FDA has approved ripretinib for the treatment of adults with advanced GIST who have received therapy with ≥3 or more kinase inhibitors, including imatinib.
The FDA has approved ripretinib for the treatment of adults with advanced GIST who have received therapy with ≥3 or more kinase inhibitors, including imatinib.
The FDA has approved ripretinib...
05/15/2020
Oncology
News
04/07/2020
OS in patients with GIST is impacted more by tumor rupture than quality of surgery or treatment with adjuvant imatinib, a substudy has shown.
OS in patients with GIST is impacted more by tumor rupture than quality of surgery or treatment with adjuvant imatinib, a substudy has shown.
OS in patients with GIST is...
04/07/2020
Oncology
News
03/16/2020
Presurgery imatinib or R0 resection were the best treatment options for patients with giant GIST in a retrospective study.
Presurgery imatinib or R0 resection were the best treatment options for patients with giant GIST in a retrospective study.
Presurgery imatinib or R0...
03/16/2020
Oncology

Advertisement

News
02/10/2020
Plasma NGS was found to be valuable for detecting KIT primary and secondary mutations in patients with metastatic GIST, study findings show.
Plasma NGS was found to be valuable for detecting KIT primary and secondary mutations in patients with metastatic GIST, study findings show.
Plasma NGS was found to be...
02/10/2020
Oncology
News
01/24/2020
Review findings support the use of sunitinib dose modification guided by therapeutic drug monitoring in certain patients with RCC and GIST.
Review findings support the use of sunitinib dose modification guided by therapeutic drug monitoring in certain patients with RCC and GIST.
Review findings support the use...
01/24/2020
Oncology
News
01/09/2020
The FDA has approved avapritinib for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation.
The FDA has approved avapritinib for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation.
The FDA has approved avapritinib...
01/09/2020
Oncology

Advertisement

News
12/20/2018
Extended duration of adjuvant therapy with imatinib shows efficacy in certain patients with gastrointestinal stromal tumors, but adherence to therapy remains a challenge.
Extended duration of adjuvant therapy with imatinib shows efficacy in certain patients with gastrointestinal stromal tumors, but adherence to therapy remains a challenge.
Extended duration of adjuvant...
12/20/2018
Oncology

Advertisement